{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:15:04Z","timestamp":1786947304523,"version":"build-2736575974"},"reference-count":51,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Medical cannabis has recently been legalized in many countries, and it is currently prescribed with increasing frequency, particularly for treatment of chronic pain resistant to conventional therapy. The psychoactive substance delta-9-tetrahydro-cannabinol (THC) contained in cannabis may affect driving abilities. Therefore, the aims of this study (open-label, monocentric, nonrandomized) were to evaluate blood and saliva concentrations of THC after oral administration of medical cannabis and to assess the time needed for THC levels to decline below a value ensuring legal driving. The study involved 20 patients with documented chronic pain using long-term medical cannabis therapy. They were divided into two groups and treated with two different doses of cannabis in the form of gelatin capsules (62.5 mg or 125 mg). In all patients, the amount of THC was assessed in saliva and in blood at pre-defined time intervals before and after administration. THC levels in saliva were detected at zero in all subjects following administration of both doses at all-time intervals after administration. Assessment of THC levels in blood, however, showed positive findings in one subject 9 h after administration of the lower dose and in one patient who had been given a higher dose 7 h after administration. Our finding suggested that for an unaffected ability to drive, at least 9-10 h should elapse from the last cannabis use.<\/jats:p>","DOI":"10.33549\/physiolres.934907","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T16:05:37Z","timestamp":1672934737000},"page":"703-712","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of Delta-9-Tetrahydrocannabinol (THC) in Saliva and Blood After Oral Administration of Medical Cannabis With Respect to its Effect on Driving Abilities"],"prefix":"10.33549","author":[{"given":"V","family":"TROJAN","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"LANDA","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"HRIB","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"JURICA","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"RYCHLICKOVA","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"ZVONICEK","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia and Intensive Care Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"HALAMKOVA","sequence":"additional","affiliation":[{"name":"Institute of Environmental and Human Health, Department of Environmental Toxicology, Texas Tech University, Lubbock, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"HALAMEK","sequence":"additional","affiliation":[{"name":"Institute for Forensic Science, Department of Environmental Toxicology, Texas Tech University, Lubbock, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"DEMLOVA","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"BELASKOVA","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Centre for Translational Medicine, International Clinical Research Centre, St. Anne's University Hospital, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"SLIVA","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Third Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.\tAbuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products - Regulations in Europe and North America. Eur J Intern Med 2018;49:2-6. https:\/\/doi.org\/10.1016\/j.ejim.2018.01.001","DOI":"10.1016\/j.ejim.2018.01.001"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.\tLanda L, Jurica J, Sliva J, Pechackova M, Demlova R. Medical cannabis in the treatment of cancer pain and spastic conditions and options of drug delivery in clinical practice. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018;162:18-25. https:\/\/doi.org\/10.5507\/bp.2018.007","DOI":"10.5507\/bp.2018.007"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.\tAizpurua-Olaizola O, Soydaner U, \u00d6zt\u00fcrk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A. Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes. J Nat Prod 2016;79:324-331. https:\/\/doi.org\/10.1021\/acs.jnatprod.5b00949","DOI":"10.1021\/acs.jnatprod.5b00949"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.\tLanda L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Vet Med-Czech 2016;61:111-122. https:\/\/doi.org\/10.17221\/8762-VETMED","DOI":"10.17221\/8762-vetmed"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.\tBisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello AS, Davis JB, Mechoulam R, di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-852. https:\/\/doi.org\/10.1038\/sj.bjp.0704327","DOI":"10.1038\/sj.bjp.0704327"},{"key":"ref5","unstructured":"6.\tBridgeman MB, Abazia DT. Medicinal Cannabis: History, pharmacology, and implications for the acute care setting. P T 2017;42:180-188."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.\tStorozhuk MV, Zholos AV. TRP Channels as novel targets for endogenous ligands: Focus on endocannabinoids and nociceptive signalling. Curr Neuropharmacol 2018;16:137-150. https:\/\/doi.org\/10.2174\/1570159X15666170424120802","DOI":"10.2174\/1570159x15666170424120802"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.\tTang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin 2012;33:363-371. https:\/\/doi.org\/10.1038\/aps.2011.210","DOI":"10.1038\/aps.2011.210"},{"key":"ref8","unstructured":"9.\tAbdel-Salam OM, Salem NA, El-Sayed El-Shamarka M, Al-Said AN, Seid HJ, El-Khyat ZA. Cannabis-induced impairment of learning and memory: effect of different nootropic drugs. EXCLI J 2013;12:193-214."},{"key":"ref9","unstructured":"10.\tGrotenhermen F. Cannabinoids and the endocannabinoid system. Cannabinoids 2006;1:10-14."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.\tGaliegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le FG, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61. https:\/\/doi.org\/10.1111\/j.1432-1033.1995.tb20780.x","DOI":"10.1111\/j.1432-1033.1995.tb20780.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.\tPertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129-180. https:\/\/doi.org\/10.1016\/S0163-7258(97)82001-3","DOI":"10.1016\/s0163-7258(97)82001-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.\tVan Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003;285:G566-G576. https:\/\/doi.org\/10.1152\/ajpgi.00113.2003","DOI":"10.1152\/ajpgi.00113.2003"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.\tPertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin. Br J Pharmacol 2008;153:199-215. https:\/\/doi.org\/10.1038\/sj.bjp.0707442","DOI":"10.1038\/sj.bjp.0707442"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.\tPeng J, Fan M, An C, Ni F, Huang W, Luo J. A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD). Basic Clin Pharmacol Toxicol 2022;130:439-456. https:\/\/doi.org\/10.1111\/bcpt.13710","DOI":"10.1111\/bcpt.13710"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tGrotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012;109:495-501. https:\/\/doi.org\/10.3238\/arztebl.2012.0495","DOI":"10.3238\/arztebl.2012.0495"},{"key":"ref16","unstructured":"17.\tVerstraete AG, Legrand S-A. Drug Use, Impaired Driving and Traffic Accidents. (2nd Ed.). Luxembourg: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2014, 156 p."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.\tMechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47. https:\/\/doi.org\/10.1146\/annurev-psych-113011-143739","DOI":"10.1146\/annurev-psych-113011-143739"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tHuestis M. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770-1804. https:\/\/doi.org\/10.1002\/cbdv.200790152","DOI":"10.1002\/cbdv.200790152"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.\tZendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus LO, Jurica J. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 2016;17:206-226. https:\/\/doi.org\/10.2174\/1389200217666151210142051","DOI":"10.2174\/1389200217666151210142051"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.\tAhmed A, van den Elsen G, Colbers A, van der Marck M, Burger D, Feuth T, Rikkert M, Kramers C. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial. Eur Neuropsychopharmacol 2014;24:1475-1482. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.06.007","DOI":"10.1016\/j.euroneuro.2014.06.007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.\tKlumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM. Novel \u0394(9)-tetrahydrocannabinol formulation Namisol\u00ae has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012;74:42-53. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04164.x","DOI":"10.1111\/j.1365-2125.2012.04164.x"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.\tVandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ. Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 2017;41:83-99. https:\/\/doi.org\/10.1093\/jat\/bkx012","DOI":"10.1093\/jat\/bkx012"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.\tGaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav 2017;70:313-318. https:\/\/doi.org\/10.1016\/j.yebeh.2016.11.016","DOI":"10.1016\/j.yebeh.2016.11.016"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.\tKarschner EL, Schwilke EW, Lowe RH, Darwin WD, Herning RI, Cadet JL, Huestis MA. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol 2009;33:469-477. https:\/\/doi.org\/10.1093\/jat\/33.8.469","DOI":"10.1093\/jat\/33.8.469"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.\tLucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84:2477-2482. https:\/\/doi.org\/10.1111\/bcp.13710","DOI":"10.1111\/bcp.13710"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.\tVandrey, R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ. Pharmacokinetic profile of oral cannabis in humans: Blood and oral fluid disposition and relation to pharmacodynamic outcomes. J Anal Toxicol 2017;41:83-99. https:\/\/doi.org\/10.1093\/jat\/bkx012","DOI":"10.1093\/jat\/bkx012"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.\tAhmed AI, van den Elsen GA, Colbers A, van der Marck MA, Burger DM, Feuth TB, Rikkert MG, Kramers C. Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: A randomized controlled trial. Eur Neuropsychopharmacol 2014;24:1475-1482. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.06.007","DOI":"10.1016\/j.euroneuro.2014.06.007"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29.\tKlumpers LE, Beumer TL, van Hasselt JG, Lipplaa A, Karger LB, Kleinloog HD, Freijer JI, de Kam ML, van Gerven JM. Novel \u0394(9)-tetrahydrocannabinol formulation Namisol\u00ae has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012;74:42-53. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04164.x","DOI":"10.1111\/j.1365-2125.2012.04164.x"},{"key":"ref29","unstructured":"30.\tGWPharma. SmPC: Sativex. ed. SUKL, 2020."},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31.\tMarsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O. Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers. J Pharmacol Toxicol Methods 2017;85:49-54. https:\/\/doi.org\/10.1016\/j.vascn.2017.02.003","DOI":"10.1016\/j.vascn.2017.02.003"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32.\tGrotenhermen F, Leson G, Berghaus G, Drummer OH, Kr\u00fcger HP, Longo M, Moskowitz H, ET AL. Developing limits for driving under cannabis. Addiction 2007;102:1910-1917. https:\/\/doi.org\/10.1111\/j.1360-0443.2007.02009.x","DOI":"10.1111\/j.1360-0443.2007.02009.x"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33.\tCrean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011;5:1-8. https:\/\/doi.org\/10.1097\/ADM.0b013e31820c23fa","DOI":"10.1097\/adm.0b013e31820c23fa"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34.\tBondallaz P, Favrat B, Chtioui H, Fornari E, Maeder P, Giroud C. Cannabis and its effects on driving skills. Forensic Sci Int 2016;268:92-102. https:\/\/doi.org\/10.1016\/j.forsciint.2016.09.007","DOI":"10.1016\/j.forsciint.2016.09.007"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35.\tMartin JL, Gadegbeku B, Wu D, Viallon V, Laumon B. Cannabis, alcohol and fatal road accidents. PLoS One 2017;12:e0187320. https:\/\/doi.org\/10.1371\/journal.pone.0187320","DOI":"10.1371\/journal.pone.0187320"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36.\tArkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of cannabidiol and \u03949-tetrahydrocannabinol on driving performance a randomized clinical trial. JAMA 2020;324:2177-2186. https:\/\/doi.org\/10.1001\/jama.2020.21218","DOI":"10.1001\/jama.2020.21218"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37.\tJewett A, Peterson AB, Sauber-Schatz EK. Exploring substance use and impaired driving among adults aged 21 years and older in the US, 2015. Traffic Inj Prev 2018;19:693-700. https:\/\/doi.org\/10.1080\/15389588.2018.1479525","DOI":"10.1080\/15389588.2018.1479525"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38.\tOrtiz-Peregrina S, Ortiz C, Castro-Torres JJ, Jimenez JR, Anera RG. Effects of smoking Cannabis on visual function and driving performance. A driving-simulator based study. Int J Environ Res Public Health 2020;17:9033. https:\/\/doi.org\/10.3390\/ijerph17239033","DOI":"10.3390\/ijerph17239033"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tSevigny EL. Cannabis and driving ability. Curr Opin Psychol 2021;38:75-79. https:\/\/doi.org\/10.1016\/j.copsyc.2021.03.003","DOI":"10.1016\/j.copsyc.2021.03.003"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40.\tHryhorowicz S, Walczak M, Zakerska-Banaszak O, S\u0142omski R, Skrzypczak-Zieli\u0144ska M. Pharmacogenetics of cannabinoids. Eur J Drug Metab Pharmacokinet 2018;43:1-12. https:\/\/doi.org\/10.1007\/s13318-017-0416-z","DOI":"10.1007\/s13318-017-0416-z"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41.\tNeavyn MJ, Blohm E, Babu KM, Bird SB. Medical marijuana and driving: A review. J Med Toxicol 2014;10:269-279. https:\/\/doi.org\/10.1007\/s13181-014-0393-4","DOI":"10.1007\/s13181-014-0393-4"},{"key":"ref41","unstructured":"42.\tCollege of Family Physicians of Canada. Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada. Mississauga, 2014."},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43.\tDassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011;34:125-156. https:\/\/doi.org\/10.2165\/11539050-000000000-00000","DOI":"10.2165\/11539050-000000000-00000"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44.\tHansen RN, Boudreau DM, Ebel BE, Grossman DC, Sullivan SD. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health 2015;105:e64-e69. https:\/\/doi.org\/10.2105\/AJPH.2015.302723","DOI":"10.2105\/ajph.2015.302723"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"45.\tHerrera-Gomez F, Gutierrez-Abejon E, Alvarez FJ. Antipsychotics in the general population and the driver population: comparisons from a population-based registry study. Int Clin Psychopharmacol 2019;34:184-188. https:\/\/doi.org\/10.1097\/YIC.0000000000000263","DOI":"10.1097\/yic.0000000000000263"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"46.\tRamaekers J. Antidepressants and driving ability. Eur Psychiatry 2017;41(Suppl 1):S50-S51. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.01.214","DOI":"10.1016\/j.eurpsy.2017.01.214"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47.\tWickens CM, Mann RE, Brands B, Ialomiteanu AR, Fischer B, Watson TM, Matheson J, Stoduto G, Rehm J. Driving under the influence of prescription opioids: Self-reported prevalence and association with collision risk in a large Canadian jurisdiction. Accid Anal Prev 2018;121:14-19. https:\/\/doi.org\/10.1016\/j.aap.2018.08.026","DOI":"10.1016\/j.aap.2018.08.026"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"48.\tAviram J, Pud D, Gershoni T, Schiff-Keren B, Ogintz M, Vulfsons S, Yashar T, ET AL. Medical cannabis treatment for chronic pain: Outcomes and prediction of response. Eur J Pain 2021;25:359-374. https:\/\/doi.org\/10.1002\/ejp.1675","DOI":"10.1002\/ejp.1675"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49.\tHaroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E. The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: A prospective open-label study. Clin J Pain 2016;32:1036-1043. https:\/\/doi.org\/10.1097\/AJP.0000000000000364","DOI":"10.1097\/ajp.0000000000000364"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"50.\tSafakish R, Ko G, Salimpour V, Hendin B, Sohanpal I, Loheswaran G, Yoon SYR. Medical cannabis for the management of pain and quality of life in chronic pain patients: A prospective observational study. Pain Med 2020;21:3073-3086. https:\/\/doi.org\/10.1093\/pm\/pnaa163","DOI":"10.1093\/pm\/pnaa163"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"51.\tGrotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327-360. https:\/\/doi.org\/10.2165\/00003088-200342040-00003","DOI":"10.2165\/00003088-200342040-00003"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T16:13:22Z","timestamp":1672935202000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2022\/71_703.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":51,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934907","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}